Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib
Intern Med. 2024 Feb 12. doi: 10.2169/internalmedicine.2915-23. Online ahead of print.ABSTRACTA 36-year-old man with inverse Gottron's sign was admitted for clinically amyopathic dermatomyositis (CADM) with rapidly progressive interstitial lung disease (RP-ILD). Early addition of plasma exchange (PE) to triple therapy improved severe respiratory failure and transiently decreased serum ferritin levels and anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) titers. Furthermore, switching from tacrolimus to tofacitinib resulted in disease remission. Recognition of the inverse Gottron's sign may allow for the earlier diagnosis of anti-MDA5 Ab-positive dermatomyositis, and early addition of PE to triple therapy and administration of tofacitinib in refractory cases may be effective for anti-MDA5 Ab-positive CADM with RP-ILD under life-threatening conditions.PMID:38346740 | DOI:10.2169/internalmedicine.2915-23
Source: Internal Medicine - Category: Internal Medicine Authors: Masami Yamazoe Kazuya Takeda Yutaro Nagano Kanami Nagano Koji Kato Takashi Inoue Kazuhiro Horiuchi Kazuro Kamada Source Type: research
More News: Dermatology | Dermatomyositis | Genetics | Internal Medicine | Interstitial Lung Disease | Melanoma | Prograf | Respiratory Medicine | Skin Cancer | Tacrolimus